Myeloperoxidase, superoxide dismutase-3, cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study
The World Obesity Federation estimates that, by 2030, adult obesity rates in SA will increase to 37%
All existing efficacy evidence is animal-based
GLP-1 Activity GLP-1 receptor activation is associated with: Reduced appetite and cravings Increased satiety and fullness Slower gastric emptying Blood sugar regulation support GIP Activity GIP receptor activation is being researched for its potential role in: Metabolic regulation Insulin sensitivity support Energy balance Enhanced GLP-1 pathway activity Glucagon Receptor Activity Retatrutide also activates glucagon receptors, which researchers believe may contribute to: Increased energy expenditure Enhanced fat metabolism Greater metabolic activity Additional body composition support Because Retatrutide works across all three pathways simultaneously, many individuals researching it report: Strong appetite suppression Reduced food noise Increased fullness Sustained metabolic support Significant long-term body composition changes Research into triple-agonist peptides remains ongoing, and responses may vary significantly between individuals depending on dosage, consistency, nutrition, lifestyle, stress, sleep, hormonal balance, and overall metabolic health
